Applied DNA Reports First Fiscal Quarter 2021 Revenues at Upper End of Guided Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Applied DNA Sciences (APDN) Misses Q1 EPS by 34c
February 11, 2021 4:33 PM ESTApplied DNA Sciences (NASDAQ: APDN) reported Q1 EPS of ($0.88), $0.34 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $1.36 million.
The first quarter marked a very strong start to the fiscal year, reflecting burgeoning demand for our COVID-19 diagnostics and surveillance testing offerings (cumulatively our COVID-19 testing business). Our revenue performance was driven primarily by new client acquisitions for safeCircle, our pooled surveillance testing service, the full benefit of which we believe will be evident in our March 31, 2021 quarter. We also began to deliver quantities... More
